EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Unlocking the potential of Berberine: Advancing cancer therapy through chemosensitization and combination treatments

Anjana Sajeev, Bethsebie Sailo, Jyothsna Unnikrishnan, Ayesha Talukdar, Mohammed S Alqahtani, Mohamed Abbas, Athba Alqahtani, Gautam Sethi, Ajaikumar B Kunnumakkara

Cancer Letters · 2024-08 · 597 · 217019

DOI: 10.1016/j.canlet.2024.217019 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Letters, 2024-08. Verfasst von Anjana Sajeev und 8 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Biology Laboratory, Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati (IITG), Guwahati, Assam, 781039, Ind…. Hauptthemen laut MEDLINE: Berberine, Neoplasms, Drug Resistance, Neoplasm, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 220 Literaturangaben. Gefördert von: Department of Biotechnology, Ministry of Science and Technology, India, King Fahad Medical City, Khon Kean University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite considerable progress in cancer treatment options, resistance to chemotherapeutic drugs remains a significant challenge. This review focuses on Berberine (BBR), an isoquinoline alkaloid found in various medicinal plants, which has garnered attention in the field of oncology for its anticancer potential either alone or in combination with other compounds and its ability to modulate chemoresistance, acting as a natural chemosensitizer. BBR's ability to modulate chemoresistance is attributed to its diverse mechanisms of action, including inducing DNA breaks, inhibition of drug efflux pumps, modulation of apoptosis and necroptosis, downregulating multidrug resistance genes, enhancing immune response, suppressing angiogenesis and targeting multiple pathways within cancer cells, including protein kinase B/mammalian target of rapamycin (Akt/mTOR), epidermal growth factor receptor (EGFR), mitogen-activated protein kinase (MAPK), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), poly(ADP-ribose) polymerase (PARP1), janus kinase/signal transducers and activators of transcription (JAK-STAT), Wnt/β-catenin etc. Moreover, BBR, in combination with other compounds, also offers a promising approach to cancer therapy, enforcing its broad-spectrum anticancer effects. Therefore, this review aims to elucidate the intricate mechanism of action of BBR in combinatorial therapy as a potential chemosensitizer to increase the efficiency of several drugs, including cisplatin, doxorubicin, lapatinib, tamoxifen, irinotecan, niraparib, etc. in various cancers. Additionally, this review briefly covers the origin and biological activities of BBR, exploring the specific actions underlying its anticancer effects. Further, pharmacokinetic properties of BBR are also discussed, providing insight into its therapeutic potential and optimization of its use in cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BerberineNeoplasmsDrug Resistance, NeoplasmAntineoplastic Combined Chemotherapy ProtocolsHumansAnimalsSignal Transduction

Stichwörter der Autor:innen

BerberineChemoresistanceChemosensitizerCombination cancer therapyPharmacokinetics

Substanzen

Berberine

Autor:innen und Institutionen

  • Cancer Biology Laboratory, Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati (IITG), Guwahati, Assam, 781039, India.
  • Radiological Sciences Department, College of Applied Medical Sciences, King Khalid University, Abha, 61421, Saudi Arabia; BioImaging Unit, Space Research Centre, Michael Atiyah Building, University of Leicester, Leicest…
  • Electrical Engineering Department, College of Engineering, King Khalid University, Abha, 61421, Saudi Arabia.
  • Research Centre, King Fahad Medical City. P.O. Box: 59046, Riyadh, 11525, Saudi Arabia.
  • Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, 16 Medical Drive, 117600, Singapore; NUS Center for Cancer Research (N2CR), Yong Loo Lin School of Medicine, National Univer…
  • Cancer Biology Laboratory, Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati (IITG), Guwahati, Assam, 781039, India. Electronic address: kunnumakkara@iitg.ac.in.

Förderung

  • Department of Biotechnology, Ministry of Science and Technology, India
  • King Fahad Medical City
  • Khon Kean University
  • Council of Scientific and Industrial Research, India
  • Ministry of Education
  • Deanship of Scientific Research, King Khalid University

Zitieren

APA

Sajeev, A., Sailo, B., Unnikrishnan, J., Talukdar, A., Alqahtani, M. S., Abbas, M., Alqahtani, A., Sethi, G., & Kunnumakkara, A. B. (2024). Unlocking the potential of Berberine: Advancing cancer therapy through chemosensitization and combination treatments. Cancer Letters, 597, 217019. https://doi.org/10.1016/j.canlet.2024.217019

Vancouver

Sajeev A, Sailo B, Unnikrishnan J, Talukdar A, Alqahtani MS, Abbas M, et al. Unlocking the potential of Berberine: Advancing cancer therapy through chemosensitization and combination treatments. Cancer Letters. 2024;597:217019. doi:10.1016/j.canlet.2024.217019

BibTeX
@article{Sajeev2024,
  author = {Sajeev, Anjana and Sailo, Bethsebie and Unnikrishnan, Jyothsna and Talukdar, Ayesha and Alqahtani, Mohammed S and Abbas, Mohamed and Alqahtani, Athba and Sethi, Gautam and Kunnumakkara, Ajaikumar B},
  title = {Unlocking the potential of Berberine: Advancing cancer therapy through chemosensitization and combination treatments},
  journal = {Cancer Letters},
  year = {2024},
  volume = {597},
  pages = {217019},
  doi = {10.1016/j.canlet.2024.217019}
}
Kostenlos starten →